https://ledgergazette.com/2017/11/20/allergan-plc-agn-price-target-cut-to-191-00.html


					Posted by Joyce Ramirez on Nov 20th, 2017 // No Comments  Allergan PLC. (NYSE:AGN) had its target price dropped by equities researchers at Cantor Fitzgerald  to $191.00 in a research report issued to clients and investors on Thursday, November 2nd. The firm currently has a “neutral” rating on the stock. Cantor Fitzgerald’s price target would indicate a potential upside of 9.22% from the company’s previous close. AGN has been the subject of several other research reports. Royal Bank Of Canada  reaffirmed a “buy” rating and set a $285.00 price target on shares of Allergan PLC. in a research report on Wednesday, September 6th. Credit Suisse Group  set a $243.00 price target on shares of Allergan PLC. and gave the stock an “outperform” rating in a research report on Tuesday, October 17th. Citigroup Inc. dropped their price target on shares of Allergan PLC. from $280.00 to $240.00 and set a “buy” rating for the company in a research report on Thursday, October 19th. BidaskClub lowered shares of Allergan PLC. from a “buy” rating to a “hold” rating in a research report on Wednesday, August 9th. Finally, Wells Fargo & Company  reiterated a “buy” rating on shares of Allergan PLC. in a research note on Monday, October 2nd. One research analyst  has rated the stock with a sell rating, eleven have given a hold rating and twelve have given a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $246.73. Shares of Allergan PLC. (AGN) opened at $174.88 on Thursday. Allergan PLC. has a fifty-two week low of $169.61 and a fifty-two week high of $256.80. The stock has a market cap of $58,162.13, a PE ratio of 11.34, a price-to-earnings-growth ratio of 1.11 and a beta of 1.13. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.18 and a quick ratio of 1.08.  Allergan PLC. (NYSE:AGN) last announced its quarterly earnings results on Wednesday, November 1st. The company reported $4.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.06 by $0.09. The company had revenue of $4.03 billion for the quarter, compared to the consensus estimate of $4.04 billion. Allergan PLC. had a negative net margin of 47.27% and a positive return on equity of 8.00%. The company’s revenue for the quarter was up 11.4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $3.32 earnings per share.  equities research analysts expect that  Allergan PLC. will post 16.28 EPS for the current fiscal year.  Allergan PLC. declared that its board has authorized a stock buyback plan on Monday, September 25th that allows the company to buyback $2.00 billion in    shares. This buyback authorization allows the company to buy up to 2.8% of its stock  through open market purchases. Stock  buyback plans are often an indication that the company’s management believes its stock is undervalued.  COPYRIGHT VIOLATION NOTICE: This report was  posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this report on another website, it was illegally stolen and republished in violation of international copyright laws. The correct version of this report can be read at https://ledgergazette.com/2017/11/20/allergan-plc-agn-price-target-cut-to-191-00.html.  Several large investors have recently bought and sold shares of the company. Howard Hughes Medical Institute acquired a new position in shares of  Allergan PLC. in the second quarter worth about $103,000.  Cable Hill Partners LLC boosted its holdings in shares of  Allergan PLC. by 255.2% in the third quarter. Cable Hill Partners LLC now owns 515 shares of the company’s stock worth $106,000 after buying an additional 370 shares during the period.  Rockefeller Financial Services Inc. boosted its holdings in shares of  Allergan PLC. by 283.7% in the third quarter. Rockefeller Financial Services Inc. now owns 541 shares of the company’s stock worth $111,000 after buying an additional 400 shares during the period.  Jacobi Capital Management LLC boosted its holdings in shares of  Allergan PLC. by 4.9% in the first quarter. Jacobi Capital Management LLC now owns 472 shares of the company’s stock worth $112,000 after buying an additional 22 shares during the period.  Finally, JNBA Financial Advisors boosted its holdings in shares of  Allergan PLC. by 2.5% in the first quarter. JNBA Financial Advisors now owns 487 shares of the company’s stock worth $116,000 after buying an additional 12 shares during the period. Institutional investors own  81.65% of the company’s stock.  Allergan PLC. Company Profile Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.   Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with MarketBeat.com's FREE daily email newsletter. 

https://www.truebluetribune.com/2017/11/20/allergan-plc-agn-price-target-cut-to-191-00-by-analysts-at-cantor-fitzgerald.html


					Posted by Stefani Robinson on Nov 20th, 2017 // No Comments  Allergan PLC. (NYSE:AGN) had its price objective dropped by analysts at Cantor Fitzgerald  to $191.00 in a report released on Thursday, November 2nd. The brokerage presently has a “neutral” rating on the stock. Cantor Fitzgerald’s target price would indicate a potential upside of 9.22% from the stock’s current price. Several other analysts have also commented on the company. Wells Fargo & Company  reaffirmed an “outperform” rating and set a $245.00 target price (down from $258.00) on shares of Allergan PLC. in a report on Thursday, November 2nd. Royal Bank Of Canada lowered their price target on Allergan PLC. from $250.00 to $221.00 and set an “outperform” rating on the stock in a research report on Thursday, November 2nd. Zacks Investment Research upgraded Allergan PLC. from a “sell” rating to a “hold” rating in a research report on Monday, October 23rd. J P Morgan Chase & Co  set a $275.00 price target on Allergan PLC. and gave the stock a “buy” rating in a research report on Sunday, October 22nd. Finally, Cowen and Company  set a $280.00 price target on Allergan PLC. and gave the stock a “buy” rating in a research report on Friday, October 20th. One investment analyst  has rated the stock with a sell rating, eleven have issued  a hold rating and twelve have assigned  a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus target price of $246.73. Allergan PLC. (NYSE AGN) opened at $174.88 on Thursday. Allergan PLC. has a 1 year low of $169.61 and a 1 year high of $256.80. The stock has a market capitalization of $58,162.13, a PE ratio of 11.34, a P/E/G ratio of 1.11 and a beta of 1.13. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.08 and a current ratio of 1.18.  Allergan PLC. (NYSE:AGN) last announced its quarterly earnings data on Wednesday, November 1st. The company reported $4.15 earnings per share for the quarter, beating analysts’ consensus estimates of $4.06 by $0.09. The business had revenue of $4.03 billion for the quarter, compared to analyst estimates of $4.04 billion. Allergan PLC. had a positive return on equity of 8.00% and a negative net margin of 47.27%. The company’s revenue was up 11.4% on a year-over-year basis. During the same period in the prior year, the company earned $3.32 earnings per share.  equities analysts predict that  Allergan PLC. will post 16.28 earnings per share for the current fiscal year.  Allergan PLC. announced that its board has authorized a stock buyback plan on Monday, September 25th that permits the company to repurchase $2.00 billion in    shares. This repurchase authorization permits the company to repurchase up to 2.8% of its shares through open market purchases. Shares repurchase plans are often a sign that the company’s board believes its shares are undervalued.  Institutional investors have recently bought and sold shares of the company. Cipher Capital LP acquired a new position in  Allergan PLC. in the 1st quarter valued at about $853,000.  Hugh Johnson Advisors LLC increased its position in  Allergan PLC. by 3.5% in the 1st quarter. Hugh Johnson Advisors LLC now owns 10,042 shares of the company’s stock valued at $2,399,000 after acquiring an additional 340 shares during the period.  Atlantic Trust Group LLC increased its position in  Allergan PLC. by 17.7% in the 1st quarter. Atlantic Trust Group LLC now owns 644,643 shares of the company’s stock valued at $154,019,000 after acquiring an additional 97,079 shares during the period.  Sandy Spring Bank increased its position in  Allergan PLC. by 5.5% in the 1st quarter. Sandy Spring Bank now owns 10,120 shares of the company’s stock valued at $2,417,000 after acquiring an additional 530 shares during the period.  Finally, Schroder Investment Management Group increased its position in  Allergan PLC. by 133.3% in the 1st quarter. Schroder Investment Management Group now owns 417,948 shares of the company’s stock valued at $100,225,000 after acquiring an additional 238,796 shares during the period. 81.65% of the stock is owned by institutional investors and hedge funds.  About Allergan PLC. Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.   Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with MarketBeat.com's FREE daily email newsletter. 

http://www.tradingnewsnow.com/2017/11/20/worth-watching-stock-news-alert-allergan-plc-nyse-agn-iron-mountain-incorporated-nyse-irm-nvidia-corporation-nasdaq-nvda-real-goods-solar-inc-nasdaq-rgse/

Snapshot:Allergan plc, belongs to Healthcare sector and Drugs – Generic industry. Intraday Trading of Allergan plc: The Healthcare stock (Allergan plc) showed a change of 0.51 percent from opening and finally turned off its business at $174.88 by scoring 0.04 percent on Friday. Trading volume, or volume, is the number of shares or contracts that point towards the overall activity of a security or market for a given period. The company exchanged hands with 2804316 shares compared to its average daily volume of 3.49M shares. Historical Performances under Review: Over the last week, Allergan plc’s shares returned 1.55 percent and in the past 30.0 days the figure appeared at -7.6 percent. Furthermore, over the 90.0 days, the stock was able to yield -21.57 percent. However, -20.34 percent is noted as its 180 days or half-yearly performance. The current EPS for the company has been recorded at $-22.57. By applying the formula, the price-earnings (P/E) ratio comes out to be 0. Major Indicators to Watch: The Allergan plc has 334.11M shares outstanding with 0.1 percent insider ownership. The stock has weekly volatility of 2.41 percent and monthly volatility of 2.95 percent with ATR of 5.26 and beta of 1.13. Risk administration is a fundamental process used to make investment decisions. Beta measures the amount of systematic risk a security has relative to the whole market. The market has a beta of 1, and it can be used to gauge the risk of a security. The AGN is trading away to its 20-days, 50-day and 200-day moving averages by -1.39 percent, -11.24 percent and -23.14 percent, respectively. Iron Mountain Incorporated, belongs to Technology sector and Business Software & Services industry. (NYSE: IRM) has grabbed attention from the analysts when it practiced a change of -0.12 percent in the last trading session to close at $40.77. A total of 1326077 shares exchanged hands during the intra-day trade contrast with its average trading volume of 1.19M shares, while its relative volume stands at 1.11. IRM has market value of $10.87B while its EPS was booked as $0.81 in the last 12 months. The stock has 266.74M shares outstanding. In the profitability analysis, the company has gross profit margin of 55.8 percent while net profit margin was 5.5 percent. Trading volume is a gauge of how many times a stock is bought and sold in a given time period (most commonly, within a day of trading, known as the average daily trading volume – ADTV). A high degree of volume indicates a lot of interest in a stock. Often, a boost in the volume of a stock is a harbinger of a price jump, either up or down. ATR stands at 0.59 while Beta factor of the stock stands at 1.04. Beta factor is used to measure the volatility of the stock. After a recent check, company stock is found to be 1.43 percent volatile for the week, while 1.43 percent volatility is recorded for the month. Most company stocks have very little volatility. They generally move extremely slowly and they only produce big price swings when the company produces good or bad trading results, which may only happen a couple of times a year at best. The company’s distance from 52-week high price is -1 percent and the current price is 30.3 percent away from 52-week low price. The company has Relative Strength Index (RSI 14) of 56.34. Performance Review Of Iron Mountain Incorporated, (NYSE: IRM): The stock has shown weekly performance of 0.27 percent and monthly performance stands at -0.46 percent. The stock has shown quarterly performance of 8.49 percent and a half-year performance stands at 17.12 percent. Analyst recommendation for this stock stands at 2.5. NVIDIA Corporation, (NASDAQ: NVDA) make a change of -0.12 percent with the overall traded volume of 12856672 shares as compare to its average volume of 14.62M shares. The company has the market value of $126.18B and its EPS ratio for the past year was $3.49. The company turned off its business at $211.36. NVIDIA Corporation, belongs to Technology sector and Semiconductor – Specialized industry. Technical Analysis in the Limelight: The organization has 597.00M shares outstanding and 67.7 percent shares of the company were owned by institutional shareholders. The company has 15.12 value in price to sale ratio while price to book ratio was recorded as 21.11. It beta stands at 1.2. The average true range of the stock is recorded at 4.99 and the relative strength index of the stock stands 61.05. The stock has shown its weekly performance of -2.21 percent and monthly performance stands at 6.86 percent. The stock price is moving from its 200 days moving average with 2.69 percent and from 50 days moving average with 10.36 percent. Analyst recommendation for this stock stands at 2.4. Real Goods Solar, Inc., (NASDAQ: RGSE), plunged 5.17 percent with the closing price of $1.83. The overall volume in the last trading session was 1151075 shares. Real Goods Solar, Inc., belongs to Industrial Goods sector and General Building Materials industry. According to Real Goods Solar, Inc..’s Insider ownership is at 6.1 percent. The total amount of shares outstanding is 7.15M, giving the company a market capitalization of about 13.08M. The stock has seen its SMA50 which is now 18.2 percent. In looking the SMA 200 we see that the stock has seen a 44.63percent.The Company’s net profit margin for the 12 months at 0 percent. Comparatively, the gazes have a Gross margin -5.4 percent. Profitability ratios of RGSE: Looking into the profitability ratios of RGSE stock, a shareholder will find its ROE, ROA, ROI standing at -822.3 percent, -121.6 percent and -200.1 percent, respectively. Earnings per Share Details of Real Goods Solar, Inc.: The EPS of RGSE is strolling at -331.44, measuring its EPS growth this year at 74.1 percent. As a result, the company has an EPS growth of 0 percent for the approaching year. Given the importance of identifying companies that will ensure earnings per share at a tall rate, we later obsession to umpire how to identify which companies will achieve high amassing rates. One obvious showing off to identify high earnings per portion count together companies are to locate companies that have demonstrated such build up beyond the p.s. 5 to 10 years. We can’t have enough maintenance the once will always reflect the difficult, but logically stocks that have grown earnings per allowance strongly in the subsequent to are a fine bet to continue to take effect as a result. Company’s EPS for the past five years is valued at 28 percent leading it to an EPS value of 0 percent for the next five years. Performance Review in Focus: Taking a look at the performance of RGSE stock, an investor will come to know that the weekly performance for this stock is valued at 6.4, resulting in a performance for the month at -22.13 percent. Therefore, the stated figure displays a quarterly performance of 161.43 percent, bringing six-month performance to 72.64 percent and year to date performance of -74.64 percent. As of now, Real Goods Solar, Inc. has a P/S, P/E and P/B values of 0.92, 0 and 0.7 respectively. Its P/Cash is valued at 0.93. 

https://stocknewstimes.com/2017/11/19/cantor-fitzgerald-analysts-give-allergan-plc-agn-a-231-00-price-target.html


					Posted by Candace Mills on Nov 19th, 2017 // No Comments  Allergan PLC. (NYSE:AGN) has been given a $231.00 price target by equities researchers at Cantor Fitzgerald  in a report released on Wednesday, November 1st. The brokerage presently has a “hold” rating on the stock. Cantor Fitzgerald’s target price points to a potential upside of 32.09% from the company’s current price. A number of other equities research analysts have also recently weighed in on the stock. Mizuho  reiterated a “buy” rating and set a $267.00 price target on shares of Allergan PLC. in a research report on Wednesday, August 2nd. Royal Bank Of Canada  set a $285.00 price objective on shares of Allergan PLC. and gave the company a “buy” rating in a research note on Thursday, August 3rd. Wells Fargo & Company lifted their price target on shares of Allergan PLC. to $278.00 and gave the stock an “outperform” rating in a research note on Thursday, August 3rd. Deutsche Bank AG  reiterated a “buy” rating and issued a $273.00 price target (up previously from $265.00) on shares of Allergan PLC. in a research note on Monday, July 17th. Finally, Credit Suisse Group  reiterated an “outperform” rating and issued a $286.00 price target (up previously from $274.00) on shares of Allergan PLC. in a research note on Thursday, July 20th. One investment analyst  has rated the stock with a sell rating, eleven have assigned  a hold rating and twelve have issued  a buy rating to the stock. Allergan PLC. presently has a consensus rating of “Hold” and a consensus price target of $246.73. Allergan PLC. (AGN) traded up $0.07 on Wednesday, reaching $174.88. 2,802,315 shares of the company’s stock traded hands, compared to its average volume of 4,396,769. The company has a current ratio of 1.18, a quick ratio of 1.08 and a debt-to-equity ratio of 0.40. The stock has a market capitalization of $58,162.13, a P/E ratio of 11.34, a price-to-earnings-growth ratio of 1.11 and a beta of 1.13. Allergan PLC. has a fifty-two week low of $169.61 and a fifty-two week high of $256.80.  Allergan PLC. (NYSE:AGN) last posted its quarterly earnings results on Wednesday, November 1st. The company reported $4.15 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $4.06 by $0.09. Allergan PLC. had a negative net margin of 47.27% and a positive return on equity of 8.00%. The firm had revenue of $4.03 billion for the quarter, compared to the consensus estimate of $4.04 billion. During the same period last year, the firm posted $3.32 earnings per share. The company’s revenue for the quarter was up 11.4% on a year-over-year basis.  sell-side analysts expect that  Allergan PLC. will post 16.28 earnings per share for the current fiscal year.  Allergan PLC. declared that its Board of Directors has approved a share repurchase plan on Monday, September 25th that allows the company to buyback $2.00 billion in  outstanding  shares. This buyback authorization allows the company to purchase up to 2.8% of its shares through open market purchases. Shares buyback plans are usually a sign that the company’s board believes its shares are undervalued.  Several institutional investors and hedge funds have recently modified their holdings of the company. Veritas Asset Management LLP acquired a new position in  Allergan PLC. during the first quarter worth about $761,339,000.  Edgewood Management LLC boosted its position in shares of  Allergan PLC. by 24.3% in the 3rd quarter. Edgewood Management LLC now owns 4,445,924 shares of the company’s stock valued at $911,192,000 after purchasing an additional 869,248 shares during the period.  Baupost Group LLC MA boosted its position in shares of  Allergan PLC. by 21.9% in the 3rd quarter. Baupost Group LLC MA now owns 2,964,203 shares of the company’s stock valued at $607,513,000 after purchasing an additional 531,600 shares during the period.  Renaissance Technologies LLC acquired a new position in shares of  Allergan PLC. in the 1st quarter valued at $124,255,000.  Finally, Asset Management One Co. Ltd. boosted its position in shares of  Allergan PLC. by 4,852.6% in the 3rd quarter. Asset Management One Co. Ltd. now owns 503,088 shares of the company’s stock valued at $103,108,000 after purchasing an additional 492,930 shares during the period. 81.65% of the stock is currently owned by institutional investors.  Allergan PLC. Company Profile Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.   Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with MarketBeat.com's FREE daily email newsletter. 

https://www.dispatchtribunal.com/2017/11/20/allergan-plc-agn-price-target-cut-to-221-00-by-analysts-at-royal-bank-of-canada.html


					Posted by Lisa Durand on Nov 20th, 2017 // No Comments  Allergan PLC. (NYSE:AGN) had its target price dropped by stock analysts at Royal Bank Of Canada  from $250.00 to $221.00 in a report released on Thursday, November 2nd, MarketBeat reports. The brokerage presently has an “outperform” rating on the stock. Royal Bank Of Canada’s target price would indicate a potential upside of 26.37% from the company’s current price. A number of other equities analysts also recently issued reports on AGN. Zacks Investment Research upgraded Allergan PLC. from a “hold” rating to a “buy” rating and set a $270.00 price target for the company in a research note on Tuesday, July 11th. Piper Jaffray Companies  reissued a “hold” rating and set a $231.00 target price on shares of Allergan PLC. in a research report on Friday, July 14th. Deutsche Bank AG  reissued a “buy” rating and set a $273.00 target price (up previously from $265.00) on shares of Allergan PLC. in a research report on Monday, July 17th. Credit Suisse Group  reissued an “outperform” rating and set a $286.00 target price (up previously from $274.00) on shares of Allergan PLC. in a research report on Thursday, July 20th. Finally, Mizuho  reissued a “buy” rating and set a $267.00 target price on shares of Allergan PLC. in a research report on Wednesday, August 2nd. One research analyst  has rated the stock with a sell rating, eleven have given a hold rating and twelve have given a buy rating to the company’s stock. The company  has a consensus rating of “Hold” and a consensus price target of $246.73. Shares of Allergan PLC. (NYSE AGN) opened at $174.88 on Thursday. The company has a current ratio of 1.18, a quick ratio of 1.08 and a debt-to-equity ratio of 0.40. Allergan PLC. has a 1-year low of $169.61 and a 1-year high of $256.80. The firm has a market capitalization of $58,160.00, a PE ratio of 11.34, a price-to-earnings-growth ratio of 1.11 and a beta of 1.12.  Allergan PLC. (NYSE:AGN) last issued its earnings results on Wednesday, November 1st. The company reported $4.15 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $4.06 by $0.09. The company had revenue of $4.03 billion during the quarter, compared to the consensus estimate of $4.04 billion. Allergan PLC. had a positive return on equity of 8.00% and a negative net margin of 47.27%. The firm’s revenue for the quarter was up 11.4% compared to the same quarter last year. During the same period last year, the business posted $3.32 EPS.  sell-side analysts predict that  Allergan PLC. will post 16.28 earnings per share for the current year.  Allergan PLC. announced that its board has authorized a stock repurchase program on Monday, September 25th that allows the company to repurchase $2.00 billion in    shares. This repurchase authorization allows the company to repurchase up to 2.8% of its shares through open market purchases. Shares repurchase programs are usually a sign that the company’s leadership believes its stock is undervalued.  ILLEGAL ACTIVITY NOTICE: This news story was  reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this news story on another domain, it was copied illegally and republished in violation of international copyright and trademark legislation. The legal version of this news story can be read at https://www.dispatchtribunal.com/2017/11/20/allergan-plc-agn-price-target-cut-to-221-00-by-analysts-at-royal-bank-of-canada.html.  A number of institutional investors have recently bought and sold shares of AGN. Veritas Asset Management LLP purchased a new stake in  Allergan PLC. in the first quarter worth about $761,339,000.  Edgewood Management LLC grew its holdings in  Allergan PLC. by 24.3% in the third quarter. Edgewood Management LLC now owns 4,445,924 shares of the company’s stock worth $911,192,000 after purchasing an additional 869,248 shares during the period.  Baupost Group LLC MA grew its holdings in  Allergan PLC. by 21.9% in the third quarter. Baupost Group LLC MA now owns 2,964,203 shares of the company’s stock worth $607,513,000 after purchasing an additional 531,600 shares during the period.  Renaissance Technologies LLC purchased a new stake in  Allergan PLC. in the first quarter worth about $124,255,000.  Finally, Asset Management One Co. Ltd. grew its holdings in  Allergan PLC. by 4,852.6% in the third quarter. Asset Management One Co. Ltd. now owns 503,088 shares of the company’s stock worth $103,108,000 after purchasing an additional 492,930 shares during the period. 81.65% of the stock is owned by institutional investors and hedge funds.  About Allergan PLC. Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.   Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with MarketBeat.com's FREE daily email newsletter. 

https://rivesjournal.com/trading-spotter-tracking-shares-of-allergan-plc-agn-2/439068/


Monitoring the indicators on shares of Allergan Plc (AGN), we have spotted the 21 day Wilder Moving Average under the 50 day SMA . With this reading, traders may be looking to gauge the near-term trend.
Some investors may find the Williams Percent Range or Williams %R as a helpful technical indicator. Presently, Allergan Plc (AGN)’s Williams Percent Range or 14 day Williams %R is resting at -71.89. Values can range from 0 to -100. A reading between -80 to -100 may be typically viewed as strong oversold territory. A value between 0 to -20 would represent a strong overbought condition. As a momentum indicator, the Williams R% may be used with other technicals to help define a specific trend.
Moving averages can help spot trends and price reversals. They may also be used to help find support or resistance levels. Moving averages are considered to be lagging indicators meaning that they confirm trends. A certain stock may be considered to be on an uptrend if trading above a moving average and the average is sloping upward. On the other side, a stock may be considered to be in a downtrend if trading below the moving average and sloping downward. Shares of Allergan Plc (AGN) have a 7-day moving average of 173.45.
Technical traders often make a point of keeping an eye on the ATR or Average True Range of a particular equity. Currently, Allergan Plc (AGN) has a 14-day ATR of 5.10. The Average True Range is an investor tool used to measure stock volatility. The ATR is not used to figure out price direction, just to measure volatility. The ATR is an indicator developed by J. Welles Wilder. Wilder has developed multiple indicators that are still quite popular in today’s investing landscape. The general interpretation of the ATR is the higher the ATR value, the higher the volatility.
One technical indicator that may help gauge the strength of market momentum is the Average Directional Index or ADX. At the time of writing, the 14-day ADX for Allergan Plc (AGN) is standing at 33.18. The ADX was created by J. Welles Wilder to help determine how strong a trend is. In general, a rising ADX line means that an existing trend is gaining strength. The opposite would be the case for a falling ADX line. Many chart analysts believe that an ADX reading over 25 would suggest a strong trend. A reading under 20 would suggest no trend, and a reading from 20-25 would suggest that there is no clear trend signal.
Tracking other technical indicators, the 14-day RSI is presently standing at 37.73, the 7-day sits at 46.19, and the 3-day is resting at 65.72 for Allergan Plc (AGN). The Relative Strength Index (RSI) is a highly popular technical indicator. The RSI is computed base on the speed and direction of a stock’s price movement. The RSI is considered to be an internal strength indicator, not to be confused with relative strength which is compared to other stocks and indices. The RSI value will always move between 0 and 100. One of the most popular time frames using RSI is the 14-day. 








LoadPopupRatings('MBAP-Popup-MBAP-Popup-rivesjournal', 'NYSE:AGN', 'Allergan Plc', 'http://davidsonregister.com/wp-content/uploads/2017/02/davidon.png');

 Monitoring the indicators on shares of Allergan Plc (AGN), we have spotted the 21 day Wilder Moving Average under the 50 day SMA . With this reading, traders may be looking to gauge the near-term trend. Some investors may find the Williams Percent Range or Williams %R as a helpful technical indicator. Presently, Allergan Plc (AGN)’s Williams Percent Range or 14 day Williams %R is resting at -71.89. Values can range from 0 to -100. A reading between -80 to -100 may be typically viewed as strong oversold territory. A value between 0 to -20 would represent a strong overbought condition. As a momentum indicator, the Williams R% may be used with other technicals to help define a specific trend. Moving averages can help spot trends and price reversals. They may also be used to help find support or resistance levels. Moving averages are considered to be lagging indicators meaning that they confirm trends. A certain stock may be considered to be on an uptrend if trading above a moving average and the average is sloping upward. On the other side, a stock may be considered to be in a downtrend if trading below the moving average and sloping downward. Shares of Allergan Plc (AGN) have a 7-day moving average of 173.45. Technical traders often make a point of keeping an eye on the ATR or Average True Range of a particular equity. Currently, Allergan Plc (AGN) has a 14-day ATR of 5.10. The Average True Range is an investor tool used to measure stock volatility. The ATR is not used to figure out price direction, just to measure volatility. The ATR is an indicator developed by J. Welles Wilder. Wilder has developed multiple indicators that are still quite popular in today’s investing landscape. The general interpretation of the ATR is the higher the ATR value, the higher the volatility. One technical indicator that may help gauge the strength of market momentum is the Average Directional Index or ADX. At the time of writing, the 14-day ADX for Allergan Plc (AGN) is standing at 33.18. The ADX was created by J. Welles Wilder to help determine how strong a trend is. In general, a rising ADX line means that an existing trend is gaining strength. The opposite would be the case for a falling ADX line. Many chart analysts believe that an ADX reading over 25 would suggest a strong trend. A reading under 20 would suggest no trend, and a reading from 20-25 would suggest that there is no clear trend signal. Tracking other technical indicators, the 14-day RSI is presently standing at 37.73, the 7-day sits at 46.19, and the 3-day is resting at 65.72 for Allergan Plc (AGN). The Relative Strength Index (RSI) is a highly popular technical indicator. The RSI is computed base on the speed and direction of a stock’s price movement. The RSI is considered to be an internal strength indicator, not to be confused with relative strength which is compared to other stocks and indices. The RSI value will always move between 0 and 100. One of the most popular time frames using RSI is the 14-day.           

 

http://www.tradingnewsnow.com/2017/11/20/worth-watching-stock-news-alert-allergan-plc-nyse-agn-iron-mountain-incorporated-nyse-irm-nvidia-corporation-nasdaq-nvda-real-goods-solar-inc-nasdaq-rgse/

Snapshot:Allergan plc, belongs to Healthcare sector and Drugs – Generic industry. Intraday Trading of Allergan plc: The Healthcare stock (Allergan plc) showed a change of 0.51 percent from opening and finally turned off its business at $174.88 by scoring 0.04 percent on Friday. Trading volume, or volume, is the number of shares or contracts that point towards the overall activity of a security or market for a given period. The company exchanged hands with 2804316 shares compared to its average daily volume of 3.49M shares. Historical Performances under Review: Over the last week, Allergan plc’s shares returned 1.55 percent and in the past 30.0 days the figure appeared at -7.6 percent. Furthermore, over the 90.0 days, the stock was able to yield -21.57 percent. However, -20.34 percent is noted as its 180 days or half-yearly performance. The current EPS for the company has been recorded at $-22.57. By applying the formula, the price-earnings (P/E) ratio comes out to be 0. Major Indicators to Watch: The Allergan plc has 334.11M shares outstanding with 0.1 percent insider ownership. The stock has weekly volatility of 2.41 percent and monthly volatility of 2.95 percent with ATR of 5.26 and beta of 1.13. Risk administration is a fundamental process used to make investment decisions. Beta measures the amount of systematic risk a security has relative to the whole market. The market has a beta of 1, and it can be used to gauge the risk of a security. The AGN is trading away to its 20-days, 50-day and 200-day moving averages by -1.39 percent, -11.24 percent and -23.14 percent, respectively. Iron Mountain Incorporated, belongs to Technology sector and Business Software & Services industry. (NYSE: IRM) has grabbed attention from the analysts when it practiced a change of -0.12 percent in the last trading session to close at $40.77. A total of 1326077 shares exchanged hands during the intra-day trade contrast with its average trading volume of 1.19M shares, while its relative volume stands at 1.11. IRM has market value of $10.87B while its EPS was booked as $0.81 in the last 12 months. The stock has 266.74M shares outstanding. In the profitability analysis, the company has gross profit margin of 55.8 percent while net profit margin was 5.5 percent. Trading volume is a gauge of how many times a stock is bought and sold in a given time period (most commonly, within a day of trading, known as the average daily trading volume – ADTV). A high degree of volume indicates a lot of interest in a stock. Often, a boost in the volume of a stock is a harbinger of a price jump, either up or down. ATR stands at 0.59 while Beta factor of the stock stands at 1.04. Beta factor is used to measure the volatility of the stock. After a recent check, company stock is found to be 1.43 percent volatile for the week, while 1.43 percent volatility is recorded for the month. Most company stocks have very little volatility. They generally move extremely slowly and they only produce big price swings when the company produces good or bad trading results, which may only happen a couple of times a year at best. The company’s distance from 52-week high price is -1 percent and the current price is 30.3 percent away from 52-week low price. The company has Relative Strength Index (RSI 14) of 56.34. Performance Review Of Iron Mountain Incorporated, (NYSE: IRM): The stock has shown weekly performance of 0.27 percent and monthly performance stands at -0.46 percent. The stock has shown quarterly performance of 8.49 percent and a half-year performance stands at 17.12 percent. Analyst recommendation for this stock stands at 2.5. NVIDIA Corporation, (NASDAQ: NVDA) make a change of -0.12 percent with the overall traded volume of 12856672 shares as compare to its average volume of 14.62M shares. The company has the market value of $126.18B and its EPS ratio for the past year was $3.49. The company turned off its business at $211.36. NVIDIA Corporation, belongs to Technology sector and Semiconductor – Specialized industry. Technical Analysis in the Limelight: The organization has 597.00M shares outstanding and 67.7 percent shares of the company were owned by institutional shareholders. The company has 15.12 value in price to sale ratio while price to book ratio was recorded as 21.11. It beta stands at 1.2. The average true range of the stock is recorded at 4.99 and the relative strength index of the stock stands 61.05. The stock has shown its weekly performance of -2.21 percent and monthly performance stands at 6.86 percent. The stock price is moving from its 200 days moving average with 2.69 percent and from 50 days moving average with 10.36 percent. Analyst recommendation for this stock stands at 2.4. Real Goods Solar, Inc., (NASDAQ: RGSE), plunged 5.17 percent with the closing price of $1.83. The overall volume in the last trading session was 1151075 shares. Real Goods Solar, Inc., belongs to Industrial Goods sector and General Building Materials industry. According to Real Goods Solar, Inc..’s Insider ownership is at 6.1 percent. The total amount of shares outstanding is 7.15M, giving the company a market capitalization of about 13.08M. The stock has seen its SMA50 which is now 18.2 percent. In looking the SMA 200 we see that the stock has seen a 44.63percent.The Company’s net profit margin for the 12 months at 0 percent. Comparatively, the gazes have a Gross margin -5.4 percent. Profitability ratios of RGSE: Looking into the profitability ratios of RGSE stock, a shareholder will find its ROE, ROA, ROI standing at -822.3 percent, -121.6 percent and -200.1 percent, respectively. Earnings per Share Details of Real Goods Solar, Inc.: The EPS of RGSE is strolling at -331.44, measuring its EPS growth this year at 74.1 percent. As a result, the company has an EPS growth of 0 percent for the approaching year. Given the importance of identifying companies that will ensure earnings per share at a tall rate, we later obsession to umpire how to identify which companies will achieve high amassing rates. One obvious showing off to identify high earnings per portion count together companies are to locate companies that have demonstrated such build up beyond the p.s. 5 to 10 years. We can’t have enough maintenance the once will always reflect the difficult, but logically stocks that have grown earnings per allowance strongly in the subsequent to are a fine bet to continue to take effect as a result. Company’s EPS for the past five years is valued at 28 percent leading it to an EPS value of 0 percent for the next five years. Performance Review in Focus: Taking a look at the performance of RGSE stock, an investor will come to know that the weekly performance for this stock is valued at 6.4, resulting in a performance for the month at -22.13 percent. Therefore, the stated figure displays a quarterly performance of 161.43 percent, bringing six-month performance to 72.64 percent and year to date performance of -74.64 percent. As of now, Real Goods Solar, Inc. has a P/S, P/E and P/B values of 0.92, 0 and 0.7 respectively. Its P/Cash is valued at 0.93. 

http://www.nasdaq.com/article/allergan-plc-agn-ex-dividend-date-scheduled-for-november-16-2017-cm877628

Allergan plc. ( AGN  ) will begin trading ex-dividend on November 16, 2017. A cash dividend payment of $0.7 per share is scheduled to be paid on December 15, 2017. Shareholders who purchased AGN prior to the ex-dividend date are eligible for the cash dividend payment. This marks the 4th quarter that AGN has paid the same dividend. At the current stock price of $171.82, the dividend yield is 1.63%. The previous trading day's last sale of AGN was $171.82, representing a -33.09% decrease from the 52 week high of $256.80 and a 1.3% increase over the 52 week low of $169.61. AGN is a part of the Health Care sector, which includes companies such as Johnson & Johnson ( JNJ  ) and Pfizer, Inc. ( PFE  ). AGN's current earnings per share, an indicator of a company's profitability, is -$22.5. Zacks Investment Research reports AGN's forecasted earnings growth in 2017 as 20.51%, compared to an industry average of -5.1%. For more information on the declaration, record and payment dates, visit the AGN Dividend History  page. Our  Dividend Calendar  has the full list of stocks that have an ex-dividend today.  Interested in gaining exposure to AGN through an Exchange Traded Fund [ETF]?   The following ETF(s) have AGN as a top-10 holding:  iShares U.S. Pharmaceutical ETF (   IHE    ) First Trust Nasdaq Pharmaceuticals ETF (   FTXH    ) PowerShares Dynamic Pharmaceuticals (   PJP    ) iShares MSCI Netherlands Index Fund (   EWN    ) iShares U.S. Preferred Stock ETF (   PFF    ).   The top-performing ETF of this group is EWN with an increase of 8.12% over the last 100 days. IHE has the highest percent weighting of AGN at 4.62%. 
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
 

 

https://stocknewsjournal.com/2017/11/15/allergan-plc-agn-from-top-to-bottom-4/

Allergan plc (AGN) is an interesting player in the Healthcare space, with a focus on Drugs – Generic. The stock has been active on the tape, currently trading at $171.82, down from yesterday’s close by -1.49%. Given the stock’s recent action, it seemed like a good time to take a closer look at the company’s recent data. Fundamental Analysis It’s important to get a feel for how any stock is actually valued on the market based on its core numbers. Allergan plc (AGN) currently trades with a market capitalization of $57.41 Billion. That value represents a market adjusting for revenues that have been growing by 11.38 % on a quarterly year/year basis as of the company’s last quarterly report. 
     (adsbygoogle = window.adsbygoogle || []).push({});
 The balance sheet health of any company plays a key role in its ability to meet its obligations and maintain the faith of its investment base. For AGN, the company currently has $1.61 Billion of cash on the books, which is offset by $3.8 Billion current liabilities. You can get a sense of how sustainable that is by a levered free cash flow of $3.44 Billion over the past twelve months. Generally speaking, earnings are expected to fall in coming quarters. Analysts are forecasting earnings of $4.72 on a per share basis this quarter. Perhaps, that suggests something about why 87.42% of the outstanding share supply is held by institutional investors. Technical Analysis We’ve taken a serious look at this stock from a fundamental perspective, but the tale of the tape may offer more hints about what lies under the surface. Looking at the stock’s movement on the chart, Allergan plc recorded a 52-week high of $256.80. It is now trading 84.98% off that level. The stock is trading $199.10 its 50-day moving average by 27.28%. The stock carved out a 52-week low down at $169.61. In recent action, Allergan plc (AGN) has made a move of -13.13% over the past month, which has come on Strong relative transaction volume. Over the trailing year, the stock is underperforming the S&P 500 by 18.55, and it’s gotten there by action that has been more volatile on a day-to-day basis than most other stocks on the exchange. In terms of the mechanics underlying that movement, traders will want to note that the stock is trading on a float of 2.36% with $331.78 Million sitting short, betting on future declines. That suggests something of the likelihood of a short squeeze in shares of AGN. 

https://ledgergazette.com/2017/11/15/allergan-plc-agn-given-a-250-00-price-target-at-royal-bank-of-canada.html


					Posted by Nicole Wilson on Nov 15th, 2017 // No Comments  Royal Bank Of Canada set a $250.00 price target on Allergan PLC. (NYSE:AGN)  in a research note released on Sunday, October 29th. The brokerage currently has a buy rating on the stock. The analysts noted that the move was a valuation call. Several other brokerages have also recently commented on AGN. Credit Suisse Group  set a $243.00 price target on shares of Allergan PLC. and gave the company an outperform rating in a research report on Tuesday, October 17th. Citigroup Inc. decreased their price objective on shares of Allergan PLC. from $280.00 to $240.00 and set a buy rating for the company in a research report on Thursday, October 19th. BidaskClub lowered shares of Allergan PLC. from a buy rating to a hold rating in a research note on Wednesday, August 9th. Wells Fargo & Company  reiterated a buy rating on shares of Allergan PLC. in a research note on Monday, October 2nd. Finally, Deutsche Bank AG  restated a buy rating and issued a $273.00 price objective (up from $265.00) on shares of Allergan PLC. in a research note on Monday, July 17th. One equities research analyst  has rated the stock with a sell rating, eleven have given a hold rating and twelve have issued  a buy rating to the stock. The stock  has an average rating of Hold and an average price target of $246.73. Shares of Allergan PLC. (AGN) opened at $171.82 on Friday. The stock has a market cap of $58,005.82, a PE ratio of 11.31, a PEG ratio of 1.11 and a beta of 1.13. Allergan PLC. has a 12 month low of $169.61 and a 12 month high of $256.80. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.08 and a current ratio of 1.18.  Allergan PLC. (NYSE:AGN) last issued its quarterly earnings results on Wednesday, November 1st. The company reported $4.15 earnings per share for the quarter, beating the Zacks’ consensus estimate of $4.06 by $0.09. The firm had revenue of $4.03 billion for the quarter, compared to analyst estimates of $4.04 billion. Allergan PLC. had a negative net margin of 47.27% and a positive return on equity of 8.00%. Allergan PLC.’s quarterly revenue was up 11.4% compared to the same quarter last year. During the same period last year, the company posted $3.32 EPS.  research analysts predict that  Allergan PLC. will post 16.28 earnings per share for the current year.  ILLEGAL ACTIVITY WARNING: “Allergan PLC. (AGN) PT Set at $250.00 by Royal Bank Of Canada” was originally  reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this article on another site, it was illegally stolen and republished in violation of United States and international copyright & trademark law. The legal version of this article can be read at https://ledgergazette.com/2017/11/15/allergan-plc-agn-given-a-250-00-price-target-at-royal-bank-of-canada.html.  Allergan PLC. declared that its board has initiated a share buyback program on Monday, September 25th that allows the company to repurchase $2.00 billion in  outstanding  shares. This repurchase authorization allows the company to repurchase up to 2.8% of its stock  through open market purchases. Stock  repurchase programs are often an indication that the company’s board believes its stock is undervalued.  The firm also recently declared a quarterly dividend, which will be paid on Friday, December 15th. Stockholders of record on Friday, November 17th will be given a $0.70 dividend. The ex-dividend date of this dividend is Thursday, November 16th. This represents a $2.80 dividend on an annualized basis and a dividend yield of 1.63%. Allergan PLC.’s payout ratio is currently -12.44%.  Hedge funds have recently added to or reduced their stakes in the stock. Howard Hughes Medical Institute acquired a new position in  Allergan PLC. during the 2nd quarter valued at about $103,000.  Cable Hill Partners LLC grew its stake in shares of  Allergan PLC. by 255.2% in the 3rd quarter. Cable Hill Partners LLC now owns 515 shares of the company’s stock worth $106,000 after purchasing an additional 370 shares during the last quarter.  Rockefeller Financial Services Inc. grew its stake in shares of  Allergan PLC. by 283.7% in the 3rd quarter. Rockefeller Financial Services Inc. now owns 541 shares of the company’s stock worth $111,000 after purchasing an additional 400 shares during the last quarter.  Jacobi Capital Management LLC grew its stake in shares of  Allergan PLC. by 4.9% in the 1st quarter. Jacobi Capital Management LLC now owns 472 shares of the company’s stock worth $112,000 after purchasing an additional 22 shares during the last quarter.  Finally, JNBA Financial Advisors grew its stake in shares of  Allergan PLC. by 2.5% in the 1st quarter. JNBA Financial Advisors now owns 487 shares of the company’s stock worth $116,000 after purchasing an additional 12 shares during the last quarter. 81.21% of the stock is currently owned by institutional investors and hedge funds.  Allergan PLC. Company Profile Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.   Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with MarketBeat.com's FREE daily email newsletter. 

